Biocryst Pharmaceuticals (BCRX) 7.71 $BCRX
PharmAthene (PIP) Catches Eye: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:46AM CDT
PharmAthene (PIP) was a big mover last session, as the company saw its shares rise over 6% on the day.
Corcept Therapeutics (CORT) in Focus: Stock Rises 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:39AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as its shares rose almost 6% on the day.
NPS Pharmaceuticals (NPSP) Jumps: Stock Up 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 7:51AM CDT
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day.
Nasdaq stocks posting largest percentage decreases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
BioCryst to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
GlobeNewswire - Fri May 09, 9:20AM CDT
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executivesare scheduled to present a corporate summary and update regarding the Company's development programs at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 13, 2014 at 3:00 p.m. Pacific Time.
BioCryst Pharmaceuticals Shares Down 18.7% Since SmarTrend's Sell Call (BCRX)
Comtex SmarTrend(R) - Fri May 09, 9:20AM CDT
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on April 7th, 2014 at $9.14. In approximately 1 month, BioCryst Pharmaceuticals has returned 18.66% as of today's recent price of $7.43.
BioCryst Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 5:51AM CDT
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the first quarter ended March 31, 2014.
Global Gouty Arthritis (Gout) therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34c3mc/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - UMeWorld Limited - AstraZeneca PLC - Teijin Pharma Limited - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Addex Therapeutics - BioCryst Pharmaceuticals, Inc. - Nippon Chemiphar Co., Ltd. - JW Pharmaceutical Corporation - LG Life Sciences, Ltd. - Wellstat Therapeutics Corporation - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Group - Selvita S.A - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/34..._arthritis
Global Refractory Leukemia Global Clinical Trials Report 2014 - Data for the Top Companies/Institutions
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szjj8l/refractory) has announced the addition of the "Refractory Leukemia Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Refractory Leukemia Therapeutics Clinical Trials - Sanofi - Otsuka Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Spectrum Pharmaceuticals, Inc. - Merck & Co., Inc. - Johnson & Johnson - Bristol-Myers Squibb Company - BioCryst Pharmaceuticals, Inc. - AEterna Zentaris Inc. - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Sidney Kimmel Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - National Institutes of Health Clinical Center - Seattle Children's Hospital, Research and Foundation - Children's Oncology Group - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/szjj8l/refractory
BioCryst Pharmaceuticals Has Returned 11.9% Since SmarTrend Recommendation (BCRX)
Comtex SmarTrend(R) - Mon Apr 28, 9:19AM CDT
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on April 7th, 2014 at $9.14. In approximately 3 weeks, BioCryst Pharmaceuticals has returned 11.93% as of today's recent price of $8.05.
BioCryst to Announce First Quarter 2014 Financial Results May 8
GlobeNewswire - Mon Apr 28, 6:25AM CDT
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its first quarter 2014 financial results will be released on Thursday, May 8, 2014. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
'Mad Money' Lightning Round: Hess Is Undervalued
at The Street - Sat Apr 05, 5:00AM CDT
Cramer would go with Salesforce.com but avoid BioCryst Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 04, 7:31PM CDT
Caution, not aggression, will be the rule next week, Cramer says.
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma
PR Newswire - Wed Mar 26, 10:55AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:
Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Mar 10, 8:47AM CDT
Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection
GlobeNewswire - Mon Mar 03, 5:30AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases. The Nature online publication, "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430," represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BioCryst.
BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results
GlobeNewswire - Sat Mar 01, 10:58AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161, together with details of the Company's plasma kallikrein inhibition assay. BCX4161 is currently being evaluated in a Phase 2 clinical trial, OPuS-1, as a potential treatment for the prevention of hereditary angioedema (HAE) attacks.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
BioCryst Pharmaceuticals Q4 Loss Shrinks 51% on Higher Collaborative Revenue
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 11:17AM CST
Following yesterday's double-digit gains after the Food and Drug Administration accepted its new drug application (NDA) filing for peramivir as a treatment for influenza, BioCryst Pharmaceuticals hoped to keep the good times rolling with the...
PharmAthene (PIP) Catches Eye: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:46AM CDT
PharmAthene (PIP) was a big mover last session, as the company saw its shares rise over 6% on the day.
Corcept Therapeutics (CORT) in Focus: Stock Rises 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:39AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as its shares rose almost 6% on the day.
NPS Pharmaceuticals (NPSP) Jumps: Stock Up 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 7:51AM CDT
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day.
Nasdaq stocks posting largest percentage decreases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
BioCryst to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
GlobeNewswire - Fri May 09, 9:20AM CDT
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executivesare scheduled to present a corporate summary and update regarding the Company's development programs at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 13, 2014 at 3:00 p.m. Pacific Time.
BioCryst Pharmaceuticals Shares Down 18.7% Since SmarTrend's Sell Call (BCRX)
Comtex SmarTrend(R) - Fri May 09, 9:20AM CDT
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on April 7th, 2014 at $9.14. In approximately 1 month, BioCryst Pharmaceuticals has returned 18.66% as of today's recent price of $7.43.
BioCryst Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 5:51AM CDT
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the first quarter ended March 31, 2014.
Global Gouty Arthritis (Gout) therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34c3mc/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - UMeWorld Limited - AstraZeneca PLC - Teijin Pharma Limited - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Addex Therapeutics - BioCryst Pharmaceuticals, Inc. - Nippon Chemiphar Co., Ltd. - JW Pharmaceutical Corporation - LG Life Sciences, Ltd. - Wellstat Therapeutics Corporation - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Group - Selvita S.A - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/34..._arthritis
Global Refractory Leukemia Global Clinical Trials Report 2014 - Data for the Top Companies/Institutions
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szjj8l/refractory) has announced the addition of the "Refractory Leukemia Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Refractory Leukemia Therapeutics Clinical Trials - Sanofi - Otsuka Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Spectrum Pharmaceuticals, Inc. - Merck & Co., Inc. - Johnson & Johnson - Bristol-Myers Squibb Company - BioCryst Pharmaceuticals, Inc. - AEterna Zentaris Inc. - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Sidney Kimmel Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - National Institutes of Health Clinical Center - Seattle Children's Hospital, Research and Foundation - Children's Oncology Group - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/szjj8l/refractory
BioCryst Pharmaceuticals Has Returned 11.9% Since SmarTrend Recommendation (BCRX)
Comtex SmarTrend(R) - Mon Apr 28, 9:19AM CDT
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on April 7th, 2014 at $9.14. In approximately 3 weeks, BioCryst Pharmaceuticals has returned 11.93% as of today's recent price of $8.05.
BioCryst to Announce First Quarter 2014 Financial Results May 8
GlobeNewswire - Mon Apr 28, 6:25AM CDT
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its first quarter 2014 financial results will be released on Thursday, May 8, 2014. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
'Mad Money' Lightning Round: Hess Is Undervalued
at The Street - Sat Apr 05, 5:00AM CDT
Cramer would go with Salesforce.com but avoid BioCryst Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 04, 7:31PM CDT
Caution, not aggression, will be the rule next week, Cramer says.
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma
PR Newswire - Wed Mar 26, 10:55AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:
Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Mar 10, 8:47AM CDT
Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection
GlobeNewswire - Mon Mar 03, 5:30AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases. The Nature online publication, "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430," represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BioCryst.
BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results
GlobeNewswire - Sat Mar 01, 10:58AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161, together with details of the Company's plasma kallikrein inhibition assay. BCX4161 is currently being evaluated in a Phase 2 clinical trial, OPuS-1, as a potential treatment for the prevention of hereditary angioedema (HAE) attacks.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
BioCryst Pharmaceuticals Q4 Loss Shrinks 51% on Higher Collaborative Revenue
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 11:17AM CST
Following yesterday's double-digit gains after the Food and Drug Administration accepted its new drug application (NDA) filing for peramivir as a treatment for influenza, BioCryst Pharmaceuticals hoped to keep the good times rolling with the...
